Popular:
Silence Therapeutics plc (SLN)
Intrinsic Value
DCF Not Suitable for SLN
Market cap ($0.26B) below $1B threshold — DCF not reliable for small-cap/micro-cap stocks.
Alternative Approach:
Use relative valuation (P/E, P/S) vs. peer group.
Silence Therapeutics plc (SLN) Intrinsic Value
DCF-based fair value calculation with Bear, Base, and Bull scenarios
Frequently Asked Questions
Is SLN stock undervalued or overvalued?
Insufficient data to compute DCF valuation for SLN. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.
What is SLN's intrinsic value?
Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.
How is SLN's fair value calculated?
Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For SLN, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.